Please find enclosed

August 22, 2026 The Manager Dept of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001 Scrip Code: 511509 Dear Sir/Madam, Subject : Outcome of the Board Meeting Reference : Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to the above cited subject, we would like to inform that the Board of Directors of the Company at their meeting held today, i.e. Saturday, August 22, 2026, inter-alia, approved the following: 1. The 39th Annual General Meeting (AGM) of the Company will be held on Wednesday, September 30, 2026 through Video Conferencing / Other Audio Visual Means (VC/OVAM). 2. The Boards Report, Corporate Governance Report, Management Discussion and Analysis report all its annexures for the financial year ended March 31, 2026. 3. Re-appointment of Mr. Kalyan Ram Mangipudi, Whole-Time Director (DIN: 02012580) who retires by rotation. Detailed information as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/20266 dated January 30, 2026 is enclosed as Annexure-I 4. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors has approved the re-appointment of Mr. Sri Kalyan Kompella (DIN: 03137506), Whole-time Director for period of 5(five) years November 03, 2026 until November 02, 2031, subject to the approval of Shareholders. Detailed information as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/20266 dated January 30, 2026 is enclosed as Annexure-I 5. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors has approved the re-appointment of Dr. Sankaranarayanan Alangudi (DIN: 02703392), Whole-time Director for period of 5 (five) years January 06, 2027 until January 05, 2032, subject to the approval of Shareholders. Detailed information as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/20266 dated January 30, 2026 is enclosed as Annexure-I The meeting commenced at 07:16 p.m. and concluded at 07:31 p.m. This is for your information and records. Thanking You, Yours faithfully For Vivo Bio Tech Limited Bhavish Vijayvargiya Company Secretary & Compliance Officer M. No. A77631 Encl. as above Annexure-I Disclosure of information pursuant to Regulation 30 the SEBI Listing Regulations read with Schedule III thereto and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026. S.No Particular Details Mr. Sri Kalyan Kompella Dr. Sankaranarayanan Mr. Kalyan Ram Alangudi Mangipudi 1. Reason for change viz. Re-appointment No Change. Mr. appointment, reappointment, Kalyan Ram resignation, removal, death or Mangipudi who otherwise retires by rotation and being eligible, has offered himself for reappointment 2. Date of appointment/re Appointed on August 22, Appointed on August Not Applicable appointment/cessation(as 2026 for a period of five 22, 2026 for a period of applicable) & term of (5) consecutive years i.e five (5) consecutive appointment/reappointment; November 03, 2026 until years i.e January 06, November 02, 2031 2027 until January 05, subject to approval of the 2032 subject to members at the ensuing approval of the Annual General Meeting members at the ensuing Annual General Meeting 3. Brief Profile Mr. K. Kalyan has 25 plus Dr. Sankaranarayanan Mr. M. Kalyan Ram (In case of Appointment) years of experience in the is a discovery biologist has 23 plus years of field of Accounting, and scientist with more experience in the Finance and than 45 years of field of Accounting, Administration experience in Finance and Pharmaceutical R&D. Administration. He has a proven track record in establishing drug discovery and development facilities, and implementation of GxP standards/ accreditation for various biotech /pharma facilities and blend of scientific and management experience. 4. Disclosure of relationships Not Applicable between directors (in case of appointment of a director)